Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Mark Awad, a world-renowned thoracic medical oncologist from Memorial Sloan Kettering. Together, they dived deep into the treatment landscape for metastatic non-small cell lung cancer (NSCLC) without actionable mutations in frontline settings.
Episode Highlights:
• The importance of next-generation sequencing (NGS) and PD-L1 levels in treatment decision-making.
• Current treatment options for patients with high PD-L1 scores, including single-agent immunotherapy.
• Strategies for patients with low or intermediate PD-L1 scores, including chemotherapy combined with immunotherapy.
• Discussed KRAS G12C and HER2 positive disease in second-line settings, including the latest approved therapies.
• Insights into the potential side effects and considerations when transitioning from immunotherapy to targeted therapies.
Join us as we explored the complexities of treating metastatic NSCLC and the ongoing need for clinical trials and biomarker discovery. Don't forget to check out our other episodes for more insights on treatment algorithms and recent FDA approvals!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
